Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, osilodrostat (Isturisa®) cannot be endorsed for use within NHS Wales for the treatment of endogenous Cushing’s syndrome in adults. |
||
|
||
Medicine details |
||
| Medicine name | osilodrostat (Isturisa®) | |
| Formulation | 1 mg, 5 mg and 10 mg film-coated tablet | |
| Reference number | 3104 | |
| Indication | Treatment of endogenous Cushing’s syndrome in adults |
|
| Company | Recordati Rare Diseases UK Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 15/09/2020 | |